ATE374788T1 - Polysialinsäurederivate - Google Patents

Polysialinsäurederivate

Info

Publication number
ATE374788T1
ATE374788T1 AT04768054T AT04768054T ATE374788T1 AT E374788 T1 ATE374788 T1 AT E374788T1 AT 04768054 T AT04768054 T AT 04768054T AT 04768054 T AT04768054 T AT 04768054T AT E374788 T1 ATE374788 T1 AT E374788T1
Authority
AT
Austria
Prior art keywords
polysialic acid
acid derivatives
functional group
instance
hetero
Prior art date
Application number
AT04768054T
Other languages
English (en)
Inventor
Dale H Hreczuk-Hirst
Sanjay Jain
Peter Laing
Gregory Gregoriadis
Iaonnis Papaioannou
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE374788T1 publication Critical patent/ATE374788T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/10Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04768054T 2003-08-12 2004-08-12 Polysialinsäurederivate ATE374788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03254988 2003-08-12
EP03255200 2003-08-21

Publications (1)

Publication Number Publication Date
ATE374788T1 true ATE374788T1 (de) 2007-10-15

Family

ID=34196160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768054T ATE374788T1 (de) 2003-08-12 2004-08-12 Polysialinsäurederivate

Country Status (9)

Country Link
US (4) US7691826B2 (de)
EP (1) EP1654289B1 (de)
JP (1) JP2007501888A (de)
KR (1) KR101270692B1 (de)
AT (1) ATE374788T1 (de)
DE (1) DE602004009314T2 (de)
ES (1) ES2294535T3 (de)
RU (1) RU2327703C2 (de)
WO (1) WO2005016973A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
EP1789454B1 (de) 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fraktionierung geladener polysaccharide
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2043692B1 (de) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharidderivate des erythropoietin
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
KR101654375B1 (ko) * 2007-06-26 2016-09-05 박스알타 인코퍼레이티드 가수분해성 중합체 fmoc-링커
NZ591103A (en) 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
WO2010011944A2 (en) 2008-07-25 2010-01-28 Wagner Richard W Protein screeing methods
EP2898900B1 (de) * 2008-09-19 2017-11-15 Nektar Therapeutics Polymerkonjugate von Ziconotid
PL2889043T3 (pl) 2008-12-16 2019-09-30 Genzyme Corporation Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
TW201042257A (en) * 2009-05-26 2010-12-01 Baxter Int Detection of antibody that binds to water soluble polymer-modified polypeptides
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
RU2744370C2 (ru) * 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP2474560B1 (de) * 2009-09-03 2014-03-19 The Noguchi Institute Verfahren zur herstellung eines 11-zucker-sialyloligosaccharid-peptids
RU2522846C2 (ru) * 2009-11-30 2014-07-20 Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации Лекарственный препарат и способ улучшения реологических свойств мокроты и ингаляционное применение такого препарата
JP5285022B2 (ja) * 2010-04-30 2013-09-11 旭化成株式会社 糖ペプチド誘導体及びその製造方法
RU2559522C2 (ru) * 2010-11-29 2015-08-10 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Ингаляционная лекарственная форма полисиалированной дезоксирибонуклеазы i человека и способ ее получения
JP5680576B2 (ja) * 2011-03-03 2015-03-04 旭化成株式会社 11糖シアリルオリゴ糖アスパラギンの製造方法
EP2714093A1 (de) * 2011-05-27 2014-04-09 Baxter International Inc. Therapeutische proteine mit erhöhter halbwertzeit und verfahren zu ihrer herstellung
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US20190083636A1 (en) 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2018197545A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
ES2711669A1 (es) * 2017-11-02 2019-05-06 Univ Santiago Compostela Sistemas de liberacion de farmacos de acido polisialico y metodos
US20220023430A1 (en) 2018-11-13 2022-01-27 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU675053A1 (ru) * 1977-08-10 1979-07-25 Институт Белка Ан Ссср 9-Йодацетамидо-метил-антрацен в качестве люминесцентной метки дл белков и белковоподобных полимеров
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
EP1360963B1 (de) * 1993-01-22 2007-09-12 Sloan-Kettering Institute For Cancer Research Gangliosid-KLH-Konjugatimpfstoffe mit QS-21 zur Verzögerung des Wiederauftretens eines Melanoms
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
ATE313554T1 (de) 2000-05-16 2006-01-15 Lipoxen Technologies Ltd Derivatisierung von proteinen in wässrigem lösungsmittel
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
EP2043692B1 (de) * 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharidderivate des erythropoietin

Also Published As

Publication number Publication date
EP1654289B1 (de) 2007-10-03
KR20060085329A (ko) 2006-07-26
US7691826B2 (en) 2010-04-06
DE602004009314T2 (de) 2008-02-07
ES2294535T3 (es) 2008-04-01
US20150307633A1 (en) 2015-10-29
US9920137B2 (en) 2018-03-20
KR101270692B1 (ko) 2013-06-03
RU2327703C2 (ru) 2008-06-27
JP2007501888A (ja) 2007-02-01
US20100221808A1 (en) 2010-09-02
EP1654289A1 (de) 2006-05-10
US20060270830A1 (en) 2006-11-30
WO2005016973A1 (en) 2005-02-24
US20130144043A1 (en) 2013-06-06
RU2006107545A (ru) 2007-09-27
DE602004009314D1 (de) 2007-11-15
US9102714B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
DE602004009314D1 (de) Polysialinsäurederivate
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
DE60321825D1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
DE69435105D1 (de) Derivate therapeutischer Peptide
CY1113537T1 (el) Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
ATE553780T1 (de) Ph-sensitives polymer
BRPI0408331A (pt) conjugado de polipetìdeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
DE69837095D1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
EP2298331A3 (de) Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen
BR0306675A (pt) Dispositivo para prover um número de produtos
DE60332277D1 (de) Verabreichung von sirnas
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
HUP0002985A2 (hu) Glicirrizinsavat és legalább egy antivirális hatású proteint tartalmazó vírusellenes gyógyszerkészítmény
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties